Payment overview · 2025
General Payments
$237.76
11 reported records · 5 companies
Healthcare provider profile · identity verified
William John Gill, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · WAUCHULA, FL · NPI 1427164334
Verified facts
What the public records show
CMS Open Payments records show William John Gill, PA received $237.76 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 58.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.87 | 58.4% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.32 | 14.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.28 | 11.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.77 | 10.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.52 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.76 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.21 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.76 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $33.32 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 61 |
| Gabapentin | Gabapentin | 254 | 73 |
| Lisinopril | Lisinopril | 213 | 57 |
| Losartan Potassium | Losartan Potassium | 190 | 51 |
| Famotidine | Famotidine | 172 | 40 |
| Metformin Hcl Er | Metformin Hcl | 161 | 40 |
| Tramadol Hcl | Tramadol Hcl | 158 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 44 |
| Metformin Hcl | Metformin Hcl | 149 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 39 |
| Omeprazole | Omeprazole | 147 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 38 |
| Furosemide | Furosemide | 131 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 35 |
| Trazodone Hcl | Trazodone Hcl | 124 | 34 |
| Sertraline Hcl | Sertraline Hcl | 123 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 31 |
| Meloxicam | Meloxicam | 109 | 25 |
| Montelukast Sodium | Montelukast Sodium | 106 | 29 |
| Allopurinol | Allopurinol | 102 | 27 |
| Ozempic | Semaglutide | 97 | 15 |
| Eliquis | Apixaban | 95 | 18 |
| Jardiance | Empagliflozin | 95 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 29 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 77 | 19 |
| Lorazepam | Lorazepam | 75 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 18 |
| Alprazolam | Alprazolam | 74 | 18 |
| Simvastatin | Simvastatin | 74 | 22 |
| Azelastine Hcl | Azelastine Hcl | 71 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 14 |
| Carvedilol | Carvedilol | 69 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Farxiga | Dapagliflozin Propanediol | 66 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 33 |
| Prednisone | Prednisone | 66 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 14 |
| Ezetimibe | Ezetimibe | 62 | 17 |
| Glimepiride | Glimepiride | 59 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 25 |
| Spironolactone | Spironolactone | 52 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Ibuprofen | Ibuprofen | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Pregabalin | Pregabalin | 45 | 15 |
| Celecoxib | Celecoxib | 44 | 12 |
| Atenolol | Atenolol | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Finasteride | Finasteride | 41 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 25 |
| Cefuroxime | Cefuroxime Axetil | 35 | 25 |
| Azithromycin | Azithromycin | 34 | 21 |
| Baclofen | Baclofen | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 15 |
| Risperidone | Risperidone | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.76 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, SHINGRIX, VERQUVO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error